Platform / Technology guides / Fluorescent vs. gold
Pillar guide · Detection technology
Fluorescent vs. Gold Nanoparticle Lateral Flow Assays for Cancer Biomarkers
Gold nanoparticles made the rapid test famous: a colored line anyone can read. Cancer biomarkers ask more of a test. They are monitored as numbers over time, often at low concentrations. This guide compares gold and fluorescent lateral flow assays, and explains how OncoFirm™ adds a self-calibrating reference line so a fluorescent strip can report a traceable, quantitative result at the point of care.
At a glance
Gold nanoparticle
Colored line read by eye · usually yes/no · no reader needed
Fluorescent
Glowing line measured by a reader · quantitative · reader required
OncoFirm™ adds
A fluorescent reference line on every strip, read as a test-to-reference ratio
First assays
CEA (designed 1–100 ng/mL) and PSA (designed 0.5–50 ng/mL)
Status
In development · not FDA cleared or approved · research use only first
On this page
The difference
Fluorescent vs. gold nanoparticle lateral flow: what changes
Both assay types use the same antibody sandwich on a paper strip. Gold nanoparticle assays produce a colored line that a person judges by eye. Fluorescent assays use labels that glow under excitation light, and a reader measures that light, so the result becomes a number instead of an impression.
Left: a conventional gold strip, where a faint test line becomes a judgment call. Right: an OncoFirm™ fluorescent strip with test (T), reference (R) and control (C) lines. The reader images the whole strip over time and reports the test-to-reference ratio as a calibrated value. Illustration of intended design.
The label is the only part that changes, and it changes everything downstream: how the signal is read, what kind of result comes out, and what can be done with the data afterwards.
Common labels
- ColorimetricColloidal gold
- ColorimetricColored latex
- FluorescentEuropium chelate nanoparticles
- FluorescentFluorescent latex microspheres
- FluorescentQuantum dots
- FluorescentUpconverting phosphors
Side by side
Gold vs. fluorescent vs. self-calibrating fluorescent
| Attribute | Gold nanoparticle | Conventional fluorescent | OncoFirm™ self-calibrating |
|---|---|---|---|
| Signal read by | The user's eye | A fluorescence reader | A handheld reader imaging the whole strip |
| Result type | Usually qualitative (yes/no) | Quantitative or semi-quantitative | Quantitative, in clinical units such as ng/mL |
| Lighting and observer | Strongly affect faint lines | Removed by the reader | Removed by the reader |
| Drift correction | None | External calibration and controls | Reference line on every strip (test ÷ reference) |
| Run checks | Control line only | Control line, sometimes signal checks | Control line plus timed-read flow and release checks |
| Traceability | Not applicable | Varies by product | Planned to WHO reference materials for CEA and PSA |
| Multiplexing | Limited | Well suited | Designed for panels on the same reader |
| Data | Written down by hand | Digital result | Digital record with lot, time and quality flags |
| Equipment and cost | No reader; lowest cost per test | Reader required | One reader shared across the whole test menu |
OncoFirm™ column describes design goals for a platform in development, not demonstrated performance.
Why it matters for cancer
Why cancer biomarkers need a measured signal
Change over time is the signal
CEA after colorectal cancer treatment and PSA in prostate care are followed as values. A rise between visits matters more than any single cutoff, and only a calibrated number shows it.
Low concentrations
Many tumor markers circulate at low levels. Fluorescent labels can be detected at lower signal levels than visible color, giving assay designers more room to work.
Consistency across sites
A result that does not depend on the operator’s eye or the room’s lighting can be compared between clinics, laboratories and visits.
Sensitivity alone is not enough: an assay also needs specificity, precision and clinical validation in its intended population. Read more about cancer biomarkers and tumor antigen detection.
Beyond conventional fluorescence
What a self-calibrating strip adds
Conventional fluorescent strips still depend on the reader staying calibrated. OncoFirm™ builds the calibration check into the strip itself. See the fluorescent lateral flow platform and the handheld reader.
Reference line of known brightness
Every strip carries a fluorescent reference line. Reading the test line against it corrects for reader-light and temperature drift inside each test.
Whole-strip, timed reads
The reader captures the full fluorescence profile at several time points, so flow or reagent-release problems can be flagged from the shape of the signal.
Lot calibration, traceable standards
A lot calibration curve handles reagent-lot differences, with calibration planned to trace to WHO reference materials for CEA (NIBSC 73/601) and PSA (NIBSC 17/100).
Data built for analysis
Each result is stored with lot, time and quality flags, the foundation for AI-assisted diagnostics and trend support.
Fair comparison
When a gold nanoparticle test is still the right choice
Gold remains an excellent technology. It is usually the better fit when:
- A clear yes/no answer is all the decision needs, as in many pregnancy and infectious disease screens.
- No reader or power is available, or the test must be fully disposable.
- Cost per test is the overriding constraint and high analyte levels make a visible line reliable.
- Self-testing at home needs the simplest possible format.
Trade-offs
Fluorescent trade-offs and how OncoFirm™ addresses them
A reader is required
One handheld reader carries the whole OncoFirm menu, so the cost is shared across every test it runs.
Calibration and quality control
The on-strip reference line and lot calibration curve reduce how much depends on external calibration.
Algorithm validation
Signal processing and quality checks are locked and validated with each assay before release.
Higher initial cost
Quantitative results can replace a send-out laboratory test where validated, which is the comparison that matters.
Roadmap
Where OncoFirm™ fluorescent assays are headed
Next
Multiplex panels
Several markers on one strip, from bloodborne virus to cardiac panels. All assays
FAQ
Frequently asked questions
What is the difference between fluorescent and gold nanoparticle lateral flow assays?
Both use the same antibody chemistry on a paper strip. Gold nanoparticles create a colored line that a person judges by eye. Fluorescent labels glow under excitation light, and a reader measures that light, so the result can be a number rather than a visual impression.
Are fluorescent lateral flow assays more sensitive than gold?
Often, but not automatically. Fluorescent labels can be detected at lower signal levels, but real sensitivity also depends on the antibodies, reagent optimization, the sample and the reader. Each assay has to prove its own limit of detection in validation.
Why do cancer biomarkers like CEA and PSA need quantitative results?
Clinicians usually follow CEA and PSA as values over time, looking for a meaningful rise. A yes/no line at a single cutoff hides that change, while a calibrated number can be compared from one visit to the next.
What is a self-calibrating lateral flow strip?
It is a strip that carries a fluorescent reference line of known brightness next to the test line. The reader divides the test signal by the reference signal, which corrects each result for reader-light and temperature drift inside the test itself.
Do fluorescent assays need a reader?
Yes. Fluorescence has to be excited and measured, so a reader is required. OncoFirm uses one handheld reader for its whole test menu, so the same device carries CEA, PSA and future assays.
Is the OncoFirm fluorescent platform available?
Not yet. The platform and its assays are in development, are not cleared or approved by the FDA and are not available for sale. First products are planned for research use only.
Keep reading
Related guides
Sources
References
- Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Analytical and Bioanalytical Chemistry. 2009;393:569–582. doi.org/10.1007/s00216-008-2287-2
- Bahadır EB, Sezgintürk MK. Lateral flow assays: principles, designs and labels. TrAC Trends in Analytical Chemistry. 2016;82:286–306. doi.org/10.1016/j.trac.2016.06.006
- Quesada-González D, Merkoçi A. Nanoparticle-based lateral flow biosensors. Biosensors and Bioelectronics. 2015;73:47–63. doi.org/10.1016/j.bios.2015.05.050
- National Cancer Institute. Tumor Markers. www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
- U.S. Food and Drug Administration. In Vitro Diagnostics. www.fda.gov/medical-devices/products-and-medical-procedures/in-vitro-diagnostics
Development status. The OncoFirm™ fluorescent platform and its assays are in development. They have not been cleared or approved by the FDA and are not available for sale. First products are planned for research use only. Measuring ranges are design targets, not validated performance claims.
Evaluate the platform with us
Laboratories, clinicians and research partners can help validate quantitative fluorescent CEA and PSA testing. Start a collaboration inquiry.